Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has nominated Dr. med. Nils Clausnitzer, MBA, for election to its Supervisory Board. The election will take place at the upcoming General Shareholder Meeting on June 23, 2017. In addition, Dr. Melissa Miller has joined Curetis´ Medical Advisory Board (MAB).
Dr. Clausnitzer is expected to significantly strengthen Curetis´ commercial MDx expertise at the board level. Since January 2016, Dr. Clausnitzer has been Senior Vice President and President, EMEA-APAC Lab and Distribution Services of VWR International llc./ VWR GmbH. From 2013 - 2015, he was President and Head of Commercial Operations, EMEA, and from 2010 - 2013 Vice President, Head of Commercial Operations MDx, Europe with Qiagen. Previously, Dr. Clausnitzer was Managing Director and General Manager of Abbott Diagnostics Germany and held several leadership functions with increasing responsibilities at Olympus Germany GmbH, most recently as Deputy Managing Director, General Manager Medical Service DACH. He started his professional career in 1998 in the Department for Diagnostic Radiology at University Hospital Eppendorf, Hamburg. Dr. Clausnitzer holds an MBA degree from the Open University, Milton Keynes, UK.
Dr. Melissa Miller is Professor of Pathology and Laboratory Medicine and Director, Clinical Molecular Microbiology Laboratory, as well as Associate Director, Clinical Microbiology Laboratory, at the University of North Carolina at Chapel Hill School of Medicine in the U.S.
In addition, she is the current chair of the ASM Committee on Laboratory Practices, the co-chair of the Pan American Society for Clinical Virology Professional Practices Committee, and a fellow of the American Academy of Microbiology.
"We are very pleased about adding further commercial industry and clinical expertise to our Supervisory and Medical Advisory Boards," said Dr. Oliver Schacht, CEO of Curetis. "Both Dr. Clausnitzer and Dr. Miller have a strong track record in infectious disease diagnostics, either from a commercial or a clinical angle and we look forward to working with them to further advance Curetis as a leading MDx company."